INSULINORESISTANCE IN PATIENTS WITH MASTOPATHY AND ITS EFFECT ON THE CLINICAL COURSE OF MASTOPATHY
Keywords:
mastopathy, mastalgia, insulinoresistance, metforminAbstract
Mastopathy is the most common disease in women, accounting for 90% of all mammalian diseases. The etiology of fibrous cystic mastopathy has not been fully elucidated, but many studied risk factors include endocrine disorders, particularly insulin resistance and thyroid disease.
The goal. To study the effect of metformin on the incidence of insulin resistance and the clinical course of mastopathy in patients with FCM.
Research sources and methods. The source of the study was 71 women of childbearing age (18-49) treated on the basis of the Urgench branch of the Tashkent Medical Academy on the basis of a diagnosis of fibrous cystic mastopathy. The mean age of the patients was 34.2 ± 0.4 years. Patients had an average body mass index of 31.4 ± 2.54 kg / m2 and a NOMA index of 3.2 ± 0.25.
All women underwent breast and thyroid ultrasound (UTT) using a 7.5 mHz MINDRAY DC 60 (Japan) ultrasound machine.
Conclusion. There is a strong correlation between decreased insulin resistance and the clinical course of mastopathy (r≤0.001).
There is a reliable correlation between metformin intake in women with insulin-resistant mastopathy and a decrease in UTT BIRADS category (r≤0.05).
References
Sadaf Alipour, Hadith Rastad Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical tria. DARU Journal of Pharmaceutical Sciences (2021) 29:389–396.
Sadaf Alipour, Mahboubeh Abedi. Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial BMC Endocrine Disorders (2021) 21:169 https://doi.org/10.1186/s12902-021-00824-4.
Кац И.П., Павлова Е.А., Ордиянц И.М. Роль генети¬ческих факторов и иммунных нарушений в развитии доброкачественных заболеваний молочных желез //материалы II Междисциплинарного форума «Меди¬цина молочной железы». М.: Медиабюро Статус пре¬зенс, 2012. С. 27–31.
Figueroa JD, et al. Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study. Breast Cancer Research & Treatment 2016;159(1):163-172.
Мусина Е.В., Коган И.Ю. Возможности применения бигуанидов при фиброзно-кистозной болезни у женщин репродуктивного возраста // Журнал акушерства и женских болезней. - 2019. - Т. 68. - № 3. - С. 35 - 40.
Silvera SAN, Rohan TE. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Research and Treatment. 2007;110(3):397 - 409.
Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-1123.
Gonzalez - Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16(6):1695-1700.
Boyd DB. Insulin and Cancer. Integr Cancer Ther. 2016;2(4): 315-329.
Tarique M. A Prospective Study on Prevalence of Hyperprolactinemia & Hypothyroidism in Benign Breast Diseases. Int Arch BioMed Clin Res. 2019;5(1):18 – 19.
Gunter MJ, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48–60. Abstract/FREE Full TextGoogle Scholar.
Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591.
Catsburg C., Gunter M.J., Chen C. et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 2014;74(12):3248—58.
Chelsea Catsburg, Marc J. Gunter, et al. Insulin, Estrogen, Inflammatory Markers, and Risk of Benign Proliferative Breast Disease Cancer Res; 74(12) June 15, 2014 DOI: 10.1158/0008-5472.CAN-13-3514.
Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647.
Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31- 43.
Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647.
Tu C, Ren X, He J, Zhang C, Chen R, Wang W, Li Z. The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers. J Cancer. 2019;10(24):5992-6002. [PMC free article] [PubMed].
Sonia Del Barco Metformin: Multi-faceted protection against cancer Oncotarget 2011; 2: 896 – 917.
